📣 VC round data is live. Check it out!
- Public Comps
- GoodRx
GoodRx Valuation Multiples
Discover revenue and EBITDA valuation multiples for GoodRx and similar public comparables like Yixintang Pharmaceutical, Hepsiburada, Redcare Pharmacy, Eurowag and more.
GoodRx Overview
About GoodRx
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Founded
2015
HQ

Employees
738
Website
Sectors
Financials (LTM)
EV
$1B
Valuation Multiples
Start free trialGoodRx Financials
GoodRx reported last 12-month revenue of $788M and EBITDA of $257M.
In the same LTM period, GoodRx generated $723M in gross profit, $257M in EBITDA, and $30M in net income.
Revenue (LTM)
GoodRx P&L
In the most recent fiscal year, GoodRx reported revenue of $797M and EBITDA of $271M.
GoodRx is profitable as of last fiscal year, with gross margin of 93%, EBITDA margin of 34%, and net margin of 4%.
Financial data powered by Morningstar, Inc.
GoodRx Stock Performance
GoodRx has current market cap of $989M, and enterprise value of $1B.
Market Cap Evolution
GoodRx's stock price is $2.92.
GoodRx share price increased by 23.7% in the last 30 days, and decreased by 25.5% in the last year.
GoodRx has an EPS (earnings per share) of $0.09.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $989M | 1.9% | 23.7% | 56.1% | -25.5% | $0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGoodRx Valuation Multiples
GoodRx trades at 1.6x EV/Revenue multiple, and 5.0x EV/EBITDA.
EV / Revenue (LTM)
GoodRx Financial Valuation Multiples
As of May 30, 2026, GoodRx has market cap of $989M and EV of $1B.
GoodRx has a P/E ratio of 32.5x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified GoodRx Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


GoodRx Margins & Growth Rates
GoodRx decreased revenue by 3% and EBITDA by 12% in the last fiscal year.
In the most recent fiscal year, GoodRx reported gross margin of 93%, EBITDA margin of 34%, and net margin of 4%.
GoodRx Margins
GoodRx Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
GoodRx Operational KPIs
GoodRx's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.9M for the same period.
GoodRx's Rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GoodRx's Rule of X is 24% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
GoodRx Competitors
GoodRx competitors include Yixintang Pharmaceutical, Hepsiburada, Redcare Pharmacy, Eurowag, Anhui Huaren Health, WeBuyCars, Moonpig Group, Talkspace, Aldawaa Medical Services and Medplus Health Services.
Most GoodRx public comparables operate across Health Benefits & Financial Solutions, Telemedicine & Virtual Care, Pharmacies, Vertical E-commerce, Consumer E-commerce, Price Comparison, HealthTech and FinTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.3x | 0.3x | 3.4x | 6.4x | |||
| 0.4x | 0.4x | 23.8x | 28.4x | |||
| 0.4x | 0.4x | 19.0x | 15.9x | |||
| 0.5x | 3.6x | 9.4x | 9.0x | |||
| 1.3x | - | 11.1x | - | |||
| 0.6x | 0.6x | 11.2x | 10.5x | |||
| 2.2x | 2.1x | 7.9x | 7.6x | |||
| 3.4x | 3.1x | 49.8x | 34.9x | |||
This data is available for Pro users. Sign up to see all GoodRx competitors and their valuation data. Start Free Trial | ||||||
GoodRx Funding History
Before going public, GoodRx raised $909M in total equity funding, across 3 rounds.
Last private valuation of GoodRx was $3B, after raising $100M in September 2020 from Silver Lake and TCV.
GoodRx Funding Rounds
GoodRx M&A Activity
GoodRx has acquired 6 companies to date.
Last acquisition by GoodRx was on March 7th 2022. GoodRx acquired VitaCare for $150M (EV/Revenue multiple of ).
Latest Acquisitions by GoodRx
| Description | VitaCare is a Boca Raton-headquartered technology platform that supports patient access and adherence to brand-name medications. Established in 2014, it offers services to overcome reimbursement hurdles, prescription fulfillment, and ongoing therapy management for pharmaceutical brands. The company partners with drug manufacturers to provide copay assistance, prior authorization support, and digital tools that improve treatment persistence in the United States. | RxSaver is a free prescription discount program accessible nationwide through its website, mobile app, and savings card. It negotiates discounted prices at over 68,000 pharmacies, covering brand-name and generic medications without eligibility requirements or enrollment fees. | HealthiNation is a New York-headquartered producer of health education videos distributed on YouTube, apps, and TV reaching 100 million annual views. Content spans diabetes management, smoking cessation, exercise routines, and multiple sclerosis care through channels like HealthiNation and Everyday Health. Acquired by Ziff Davis in 2016, it partners with pharma like Pfizer for sponsored series. | Scriptcycle is a prescription program manager partnering with pharmacies and PBMs to deliver cost-effective drug access. It designs transparent plans reducing out-of-pocket costs for patients in underserved communities. Scriptcycle operates nationwide, focusing on chronic disease medications and specialty pharmacy services. | |
| HQ Country | |||||
| HQ City | Boca Raton, FL | Austin, TX | New York City, NY | Asheville, NC | |
| Deal Date | 7 Mar 2022 | 13 May 2021 | 19 Apr 2021 | 31 Aug 2020 | |
| Valuation | $150M | $50M | $75M | $63M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all GoodRx acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout GoodRx
| When was GoodRx founded? | GoodRx was founded in 2015. |
| Where is GoodRx headquartered? | GoodRx is headquartered in United States. |
| How many employees does GoodRx have? | As of today, GoodRx has over 738 employees. |
| Who is the CEO of GoodRx? | GoodRx's CEO is Wendy Barnes. |
| Is GoodRx publicly listed? | Yes, GoodRx is a public company listed on Nasdaq. |
| What is the stock symbol of GoodRx? | GoodRx trades under GDRX ticker. |
| When did GoodRx go public? | GoodRx went public in 2020. |
| Who are competitors of GoodRx? | GoodRx main competitors include Yixintang Pharmaceutical, Hepsiburada, Redcare Pharmacy, Eurowag, Anhui Huaren Health, WeBuyCars, Moonpig Group, Talkspace, Aldawaa Medical Services, Medplus Health Services. |
| What is the current market cap of GoodRx? | GoodRx's current market cap is $989M. |
| What is the current revenue of GoodRx? | GoodRx's last 12 months revenue is $788M. |
| What is the current revenue growth of GoodRx? | GoodRx revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of GoodRx? | Current revenue multiple of GoodRx is 1.6x. |
| What is the current EBITDA of GoodRx? | GoodRx's last 12 months EBITDA is $257M. |
| What is GoodRx's EBITDA margin? | GoodRx's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of GoodRx? | Current EBITDA multiple of GoodRx is 5.0x. |
| What is the current FCF of GoodRx? | GoodRx's last 12 months FCF is $110M. |
| What is GoodRx's FCF margin? | GoodRx's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of GoodRx? | Current FCF multiple of GoodRx is 11.7x. |
| How many companies GoodRx has acquired to date? | As of May 2026, GoodRx has acquired 6 companies. |
| What was the largest acquisition by GoodRx? | $150M acquisition of VitaCare on 7th March 2022 was the largest M&A GoodRx has done to date. |
| What companies GoodRx acquired? | GoodRx acquired VitaCare, HealthiNation, Scriptcycle, RxSaver, HeyDoctor, and Iodine. |
| In how many companies GoodRx has invested to date? | GoodRx hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to GoodRx
Lists including GoodRx
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
